Affordable Access

Publisher Website

Identification of Naturally Processed Hepatitis C Virus-Derived Major Histocompatibility Complex Class I Ligands

Authors
Journal
PLoS ONE
1932-6203
Publisher
Public Library of Science
Publication Date
Volume
7
Issue
1
Identifiers
DOI: 10.1371/journal.pone.0029286
Keywords
  • Research Article
  • Biology
  • Biochemistry
  • Proteins
  • Immunology
  • Microbiology
  • Immunity
  • Medicine
  • Clinical Immunology
  • Gastroenterology And Hepatology
  • Liver Diseases
  • Infectious Hepatitis
  • Infectious Diseases
  • Viral Diseases
  • Hepatitis
Disciplines
  • Biology
  • Computer Science
  • Engineering
  • Medicine

Abstract

Fine mapping of human cytotoxic T lymphocyte (CTL) responses against hepatitis C virus (HCV) is based on external loading of target cells with synthetic peptides which are either derived from prediction algorithms or from overlapping peptide libraries. These strategies do not address putative host and viral mechanisms which may alter processing as well as presentation of CTL epitopes. Therefore, the aim of this proof-of-concept study was to identify naturally processed HCV-derived major histocompatibility complex (MHC) class I ligands. To this end, continuous human cell lines were engineered to inducibly express HCV proteins and to constitutively express high levels of functional HLA-A2. These cell lines were recognized in an HLA-A2-restricted manner by HCV-specific CTLs. Ligands eluted from HLA-A2 molecules isolated from large-scale cultures of these cell lines were separated by high performance liquid chromatography and further analyzed by electrospray ionization quadrupole time of flight mass spectrometry (MS)/tandem MS. These analyses allowed the identification of two HLA-A2-restricted epitopes derived from HCV nonstructural proteins (NS) 3 and 5B (NS31406–1415 and NS5B2594–2602). In conclusion, we describe a general strategy that may be useful to investigate HCV pathogenesis and may contribute to the development of preventive and therapeutic vaccines in the future.

There are no comments yet on this publication. Be the first to share your thoughts.